Stock APM APTORUM GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Aptorum Group Limited Stock

Equities

APM

KYG6096M1226

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
5.75 USD +7.08% Intraday chart for Aptorum Group Limited -29.96% +134.83%
Mar. 06 Top Midday Gainers MT
Mar. 06 YOOV Group Holding Limited entered into a entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited for $250 million in a reverse merger transaction. CI

Financials (USD)

Sales 2021 1.54 Sales 2022 1.3 Capitalization 19.64M
Net income 2021 -25M Net income 2022 -9M EV / Sales 2021 29,374,835 x
Net cash position 2021 8.15M Net Debt 2022 4.87M EV / Sales 2022 18,915,284 x
P/E ratio 2021
-2.1 x
P/E ratio 2022
-2 x
Employees 19
Yield 2021 *
-
Yield 2022
-
Free-Float 38.85%
More Fundamentals * Assessed data

Chart Aptorum Group Limited

Dynamic Chart

Latest news about Aptorum Group Limited

Top Midday Gainers MT
YOOV Group Holding Limited entered into a entered into an Agreement and Plan of Merger to acquire Aptorum Group Limited for $250 million in a reverse merger transaction. CI
Top Premarket Decliners MT
Aptorum Group Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Aptorum Group Limited Announces Chief Executive Changes CI
Aptorum Group Limited Announces Management Changes CI
Aptorum Group Limited announced that it has received $3 million in funding from Jurchen Investment Corporation CI
Top Premarket Decliners MT
Aptorum Group Obtains Nasdaq Authorization to Transfer Listing to Nasdaq Capital Market MT
Top Premarket Gainers MT
Aptorum Group Limited Announces Resignation of Thomas Lee as Head of Research and Development CI
Aptorum Group Limited announced that it has received $3 million in funding CI
Aptorum Group Limited Provides Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma CI
Biopharmaceutical Group Aptorum to Delist from Euronext Paris MT
Top Premarket Decliners MT
More news

Analyst Recommendations on Aptorum Group Limited

HC Wainwright Starts Aptorum Group at Buy With $8 Price Target MT
More recommendations

Press releases Aptorum Group Limited

Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business BU
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023 BU
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders BU
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023 BU
Aptorum : Securities Purchase Agreement - Form 6-K PU
More press releases

News in other languages on Aptorum Group Limited

Le groupe Aptorum signe une lettre d'intention et une liste de conditions pour l'acquisition d'U group
Aptorum Group annonce la publication d’un document co-écrit sur sa technologie PathsDx, un flux rapide de séquençage métagénomique objectif à faible profondeur pour le diagnostic des maladies infectieuses basé...
Aptorum Group annonce la clôture d'un billet à ordre convertible de 3 millions de dollars arrivant à échéance en 2023
Aptorum Group annonce une offre de 3 millions USD de billet à ordre convertible arrivant à échéance en 2023
Présentation d'Aptorum Group Limited à la conférence annuelle H.C. Wainwright sur les investissements mondiaux qui se tiendra du 13 au 16 septembre 2022
More news

Quotes and Performance

1 day-25.93%
1 week-37.63%
Current month-43.41%
1 month-31.51%
3 months+201.69%
6 months+165.84%
Current year+119.31%
More quotes

Highs and lows

1 week
5.04
Extreme 5.04
8.48
1 month
5.04
Extreme 5.04
11.19
Current year
1.35
Extreme 1.35
17.49
1 year
1.35
Extreme 1.35
17.49
3 years
1.35
Extreme 1.35
35.40
5 years
1.35
Extreme 1.35
332.80
10 years
1.35
Extreme 1.35
332.80
More quotes

Managers and Directors - Aptorum Group Limited

Managers TitleAgeSince
Ian Huen FOU
 Founder 44 10-09-12
Martin Siu DFI
 Director of Finance/CFO - 22-06-30
Wai-Yip Lee CTO
 Chief Tech/Sci/R&D Officer 51 19-03-31
Members of the board TitleAgeSince
Mirko Scherer BRD
 Director/Board Member 55 17-09-30
Ian Huen FOU
 Founder 44 10-09-12
Clark Cheng CTO
 Chief Tech/Sci/R&D Officer 44 18-01-01
More insiders

Quotes

Date Price Change Volume
24-04-19 5.75 +7.08% 37 257
24-04-18 5.37 -25.93% 115,771
24-04-17 7.25 -5.23% 83,247
24-04-16 7.65 -2.55% 9,975
24-04-15 7.85 -4.38% 48,179

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes

Company Profile

Aptorum Group Limited is United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The Company's business segments include Therapeutics and Non-Therapeutics. Therapeutics segment is engaged in developing various drug molecules and certain technologies for treatment of human disease conditions. Two of the Company’s lead projects, ALS-4 and SACT-1, target infectious disease and cancer, including orphan oncology indications. Non-Therapeutics segment encompasses three businesses: diagnostics projects including PathsDx Test, natural supplements including NativusWell, and AML Clinic. PathsDx Test is a novel molecular-based rapid pathogen identification and detection diagnostics technology, which is under co-development with A*STAR.
Sector
Pharmaceuticals
Calendar
2024-09-09 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
APTORUM GROUP LIMITED Stock Aptorum Group Limited
+119.31% 29.38M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+27.97% 672B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.91% 550B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.02% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+14.85% 317B
ABBVIE INC. Stock AbbVie Inc.
+6.25% 292B
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.02% 211B
NOVARTIS AG Stock Novartis AG
-0.46% 203B
ROCHE HOLDING AG Stock Roche Holding AG
-10.31% 194B
PFIZER, INC. Stock Pfizer, Inc.
-11.81% 144B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. APM Stock